Combining experimental and computational techniques to understand and improve dry powder inhalers

Introduction Dry Powder Inhalers (DPIs) continue to be developed to deliver an expanding range of drugs to treat an ever-increasing range of medical conditions; with each drug and device combination needing a specifically designed inhaler. Fast regulatory approval is essential to be first to market, ensuring commercial profitability. Areas covered In vitro deposition, particle image velocimetry, and computational modeling using the physiological geometry and representative anatomy can be combined to give complementary information to determine the suitability of a proposed inhaler design and to optimize its formulation performance. In combination, they allow the entire range of questions to be addressed cost-effectively and rapidly. Expert opinion Experimental techniques and computational methods are improving rapidly, but each needs a skilled user to maximize results obtained from these techniques. Multidisciplinary teams are therefore key to making optimal use of these methods and such qualified teams can provide enormous benefits to pharmaceutical companies to improve device efficacy and thus time to market. There is already a move to integrate the benefits of Industry 4.0 into inhaler design and usage, a trend that will accelerate.

Automated summary

Dry powder inhalers (DPIs) are crucial in the field of drug treatment, and fast regulatory approval is essential. By combining experimental techniques and computational methods, the suitable design of inhaler can be determined rapidly and its performance can be optimized. Collaborations among multidisciplinary teams can maximize the benefits for pharmaceutical companies.